Risk factor
Very high price volatility
Profitability factor
Greatly undervalued vs peers
About
Restart Life Sciences Corp., through its subsidiaries, operates as a biotechnology company worldwide. It engages in developing natural remedies specifically tailored for individuals on the autism spectrum; health-related foods that promote both mind and body wellness for healthy living, as well as psilocybin clinical trial for fragile X syndrome. The company was formerly known as Nova Mentis Life Science Corp. and changed its name to Restart Life Sciences Corp. in November 2024. Restart Life Sciences Corp. was incorporated in 2004 and is based in Vancouver, Canada.
Company Valuation
Based on key historical and expected multiples, the stock is greatly undervalued relative to its peers.
Buy
Sell